Skip to content

A Randomized Controlled Trial on the Efficacy of Acupoint Catgut Embedding Combined with Ursodeoxycholic Acid in Dissolving Cholesterol Gallstones and Its Impact on Gallbladder Function

A Randomized Controlled Trial on the Efficacy of Acupoint Catgut Embedding Combined with Ursodeoxycholic Acid in Dissolving Cholesterol Gallstones and Its Impact on Gallbladder Function

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600123552
Enrollment
Unknown
Registered
2026-04-27
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gallbladder Cholesterol Stones

Interventions

Acupoint Catgut Embedding + UDCA Group:Acupoint catgut embedding with PGLA absorbable sutures at Yanglingquan, Danshu, Riyue, and Gallbladder point, deep implantation, once every 2 weeks for 4 session
Ursodeoxycholic acid (UDCA): 10 mg/kg/day, oral nightly, for 12 weeks
Acupuncture + UDCA Group:Acupuncture at Yanglingquan, Danshu, Riyue, and Gallbladder point with superficial puncture (conventional acupuncture), once every 2 weeks for 4 sessions

Sponsors

The Third Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18–65 years; 2. Diagnosed with gallbladder cholesterol stones by ultrasonography (diameter = 10 mm); 3. Reduced gallbladder contractile function (GBEF = 35%); 4. Patency of the cystic duct; 5. No recent acute complications; 6. Voluntary signing of informed consent.

Exclusion criteria

Exclusion criteria: 1. Gallbladder pigment stones; 2. Acute cholecystitis or cholangitis; 3. Non-functioning gallbladder or severe hypokinesia; 4. Gallbladder atrophy or wall thickness > 3 mm; 5. Complete biliary obstruction; 6. Hypersensitivity to ursodeoxycholic acid (UDCA) components or absorbable materials; 7. Severe hepatic or renal dysfunction; 8. Pregnancy or lactation; 9. Contraindications related to catgut embedding (e.g., infection or ulceration at the planned embedding site; bleeding tendency).

Design outcomes

Primary

MeasureTime frame
Complete stone dissolution rate;

Secondary

MeasureTime frame
Partial stone dissolution rate;Gallbladder function recovery;Clinical symptom relief;Quality of life improvement;

Countries

China

Contacts

Public ContactXiong Zhiyong

The Third Affiliated Hospital of Sun Yat-sen University

xiongzhy5@mail.sysu.edu.cn+86 188 9853 4185

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026